Seasoned executive to leverage experience in promising new immunotherapy venture
SAN DIEGO--(BUSINESS WIRE)--Batu Biologics, a San Diego based immunotherapy company working to develop therapeutics targeting the tumor vasculature, announced today the appointment of Gerry Berg as Chief Financial Officer. In this role, Mr. Berg will report to the Chief Executive Officer.
"The significant milestones that Batu Biologics has accomplished over the past year are impressive: securing intellectual property, building a team, establishing a scientific advisory board, and validating the technology through preclinical experimentation"
Mr. Berg has over 30 years of senior management experience working with private and public companies. Mr. Berg has served a number of public companies as their Chief Executive Officer, President, Chief Financial Officer or as a financial consultant. He has also served on the Board of Directors for a number of public companies. He has managed shareholder relations, financial reviews, budgeting, contract analysis, legal services and banking relationships. Additionally, his responsibilities include compliance requirements for public companies related to the Securities and Exchange Commission and working with the Company's independent Certified Public Accountants.
"Mr. Berg brings extensive experience and leadership skills that will strengthen the implementation and execution of our financial strategies," said Samuel C. Wagner, President and Chief Executive Officer of Batu Biologics. "He is joining at a pivotal point in the development of our company and his experience will prove invaluable as we progress toward clinical trials."
Mr. Berg began his career as a Certified Public Accountant with the firm of Deloitte & Touche (Deloitte). He served as Audit Manager for the Buick Motor Division of General Motors Corporation as one of his primary assignments. Mr. Berg holds a Bachelors of Arts in Accounting from Walsh College where he graduated Cum Laude. Mr. Berg became a Certified Public Accountant (CPA) in the State of Michigan in 1979 and in the State of California in 1984.
"The significant milestones that Batu Biologics has accomplished over the past year are impressive: securing intellectual property, building a team, establishing a scientific advisory board, and validating the technology through preclinical experimentation," stated Gerry Berg. "I am excited to join this promising venture and support their vision in the next-generation of cancer therapeutics."
About Batu Biologics:
Batu Biologics is a biotechnology-based pharmaceutical company focused on the development and commercialization of novel therapies that target the "Achilles Heel of Cancer:" the tumor blood vessels. Batu's flagship therapeutic, ValloVax™, is an angiogenesis targeting cancer vaccine in the late stages of preclinical development. Batu Biologics plans to file an Investigational New Drug (IND) application for ValloVax in Q1 of 2015, seeking clinical approval to treat patients with lung cancer.
Dimitri Theofilopoulos, J.D.
Chief Operations Officer